Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04186520 · ClinicalTrials.gov registry record · Phase 1
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
A Phase 1 study of Diffuse Large B Cell Lymphoma and Follicular Lymphoma, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04186520 is a Phase 1 study of Diffuse Large B Cell Lymphoma and Follicular Lymphoma that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 100 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04186520, a Phase 1 study of Diffuse Large B Cell Lymphoma and Follicular Lymphoma, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies.
Conditions Studied
Interventions
- BIOLOGICAL 8/12-Day Production of Car-T Cells
- BIOLOGICAL 8/12-Day Production of Cryopreserved Car-T Cells
- BIOLOGICAL 12-Day Production of Car-T Cells
Study Locations (1)
Wisconsin
- Medical College of Wisconsin and Froedtert Hospital - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-05-18 |
| Est. Completion | 2029-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04186520
The ClinicalTrials.gov registry entry for NCT04186520 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (54% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which 8/12-Day Production of Car-T Cells is the first listed.
NCT04186520 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04186520 about?
NCT04186520 is a clinical study titled "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies". This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adul...
What is the current status of trial NCT04186520?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2020-05-18. Estimated completion is 2029-02-28.
What conditions does trial NCT04186520 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia (CLL), Central Nervous System Lymphoma.
What interventions are being tested in trial NCT04186520?
The interventions under investigation include: 8/12-Day Production of Car-T Cells (BIOLOGICAL), 8/12-Day Production of Cryopreserved Car-T Cells (BIOLOGICAL), 12-Day Production of Car-T Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04186520?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04186520 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
RECRUITING · Phase 1
-
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
RECRUITING · Phase 1
-
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.